Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 9123-9123 ◽  
Author(s):  
F. Joly ◽  
G. Gravis ◽  
S. Oudard ◽  
M. Soulie ◽  
B. Esterni ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Phase Iii ◽  
Self Assessment ◽  
Phase Iii Trial

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

2014 ◽  
Vol 50 (5) ◽  
pp. 953-962 ◽  
Author(s):  
Gwenaelle Gravis ◽  
Patricia Marino ◽  
Florence Joly ◽  
Stéphane Oudard ◽  
Franck Priou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Phase Iii ◽  
Self Assessment ◽  
Phase Iii Trial

scholarly journals Trend of global quality of life in localized or metastatic prostate cancer patients after treatment

2016 ◽  
Vol 27 (2) ◽  
pp. S53-S54
Author(s):  
Yao-Lin Kao ◽  
Yuh-Shyan Tsai ◽  
Zong-Ying Lin ◽  
Chien-Hui Ou ◽  
Wen-Horng Yang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Global Quality ◽  
Global Quality Of Life

scholarly journals Identification of determinants influencing quality of life in metastatic prostate cancer patients

2021 ◽  
Vol 33 ◽  
pp. S304-S305
Author(s):  
G. Tlili ◽  
E.M. Acacha ◽  
K. Ben Ahmed ◽  
S. Dziri ◽  
A. Azzebi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer

Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4681-4681 ◽  
Author(s):  
I. Latorzeff ◽  
B. Esterni ◽  
M. Habibian ◽  
G. Delplanque ◽  
C. Theodore ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Phase Iii ◽  
Phase Iii Trial

Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4571-4571 ◽  
Author(s):  
Carol Moinpour ◽  
Donna Lynn Berry ◽  
Benjamin Ely ◽  
Catherine M. Tangen ◽  
Celestia S. Higano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Phase Iii ◽  
Life Outcomes ◽  
Significance Level ◽  
Symptom Distress Scale ◽  
Distress Scale

4571 Background: The relative quality of life (QOL) for patients with newly diagnosed, metastatic prostate cancer, treated with intermittent androgen deprivation (IAD) has been assumed and hypothesized, yet never compared in a well-powered randomized trial (RT) to continuous androgen deprivation (CAD). SWOG-9346 provided such a RT in which to test QOL differences between CAD and IAD in men with metastatic prostate cancer. Methods: Patients were randomized to CAD or IAD. Patients completed the SWOG QOL Questionnaire (SF-20/SF-36, Symptom Distress Scale, treatment-specific symptoms, global QOL) at randomization and months (mo) 3, 9, and 15 post-randomization. Five QOL change scores at one time point (mo 3) were designated as primary for the QOL endpoint and are reported in this abstract: impotence, libido, energy/vitality (E/V), physical function (PF), and emotional function (EF). Significance level was adjusted for 5 comparisons (used p=0.01). Results: 615 patients in the CAD arm and 633 in the IAD arm completed the QOL questionnaire at baseline. Change between baseline and 3 months differed for the two arms with CAD reporting statistically significantly more impotence and less libido than IAD. EF was also slightly better for the IAD arm. Conclusions: These results indicate better sexual function in men receiving IAD versus CAD through post-randomization month 3. Additional benefits for IAD may include better PF, E/V and EF. Ongoing analyses will address the role of missing data, additional follow-up assessments, and resumption of therapy in the IAD arm. [Table: see text]

The Effects of GAC on the Biochemical Profiles and Quality of Life of Metastatic Prostate Cancer Patients

2006 ◽  
Vol 47 (5) ◽  
pp. 467 ◽  
Author(s):  
Sung Joon Hong ◽  
Byung Ha Chung ◽  
Jung Soo Kim ◽  
Min June Lee ◽  
Sun Yoon ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Biochemical Profiles
Sign in / Sign up

Export Citation Format

Share Document